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Abstract: Although Lyme disease remains a controversial illness, recent events have created an 
unprecedented opportunity to make progress against this serious tick-borne infection. Evidence 
presented during the legally mandated review of the restrictive Lyme guidelines of the Infec-
tious Diseases Society of America (IDSA) has confirmed the potential for persistent infection 
with the Lyme spirochete, Borrelia burgdorferi, as well as the complicating role of tick-borne 
coinfections such as Babesia, Anaplasma, Ehrlichia, and Bartonella species associated with 
failure of short-course antibiotic therapy. Furthermore, renewed interest in the role of cell 
wall-deficient (CWD) forms in chronic bacterial infection and progress in understanding the 
molecular mechanisms of biofilms has focused attention on these processes in chronic Lyme 
disease. Recognition of the importance of CWD forms and biofilms in persistent B. burgdorferi 
infection should stimulate pharmaceutical research into new antimicrobial agents that target 
these mechanisms of chronic infection with the Lyme spirochete. Concurrent clinical imple-
mentation of proteomic screening offers a chance to correct significant deficiencies in Lyme 
testing. Advances in these areas have the potential to revolutionize the diagnosis and treatment 
of Lyme disease in the coming decade.
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The gathering storm
Lyme disease is a controversial illness.1,2 Over the past decade, two opposing camps 
have emerged in the controversy over this tick-borne illness. One camp is represented by 
the Infectious Diseases Society of America (IDSA), which maintains that Lyme disease 
is a rare illness localized to well-defined areas of the world.3,4 According to IDSA, the 
disease is ‘hard to catch and easy to cure’ because the infection is rarely encountered, 
easily diagnosed in its early stage by means of accurate commercial laboratory tests, 
and effectively treated with a short course of antibiotics over 2 to 4 weeks. Chronic 
infection with the Lyme spirochete, Borrelia burgdorferi, is rare or nonexistent.3,4
The opposing camp is represented by the International Lyme and Associated 
Diseases Society (ILADS), which argues that Lyme disease is not rare and, because 
its spread is facilitated by rodents, deer, and birds, can be found in an unpredictable 
distribution around the world accompanied by other tick-borne coinfections that may 
complicate the clinical picture. According to ILADS, tickbites often go unnoticed 
and commercial laboratory testing for Lyme disease is inaccurate.1,5 Consequently the 
disease is often not recognized and may persist in a large number of patients who are 
untreated or undertreated, requiring prolonged antibiotic therapy to eradicate persistent 
infection with the evasive Lyme spirochete.1,5Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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The controversy over Lyme disease came to a head in 
November 2006 when IDSA released new guidelines severely 
limiting treatment options for patients with persistent Lyme 
symptoms.3 The guidelines were so restrictive that the 
Attorney General of Connecticut initiated an unprecedented 
investigation into potential antitrust violations by IDSA, the 
dominant infectious disease society in the United States, in 
its formulation of the guidelines.6–8 The investigation found 
significant conflicts of interest and suppression of data in the 
guidelines development process.6,7 As a result, IDSA created 
a new scientific panel to review its Lyme guidelines in a 
process under the complete control of IDSA.8,9 The review 
panel held a hearing in July 2009 that was broadcast live 
over the internet and featured more than 300 peer-reviewed 
articles and 1600 pages of analysis supporting the concept 
of persistent infection despite short-course antibiotic therapy 
of 2 to 4 weeks in patients with persistent Lyme disease 
symptoms.8,9 Despite this extensive evidence, the IDSA 
review panel voted unanimously to uphold the flawed Lyme 
guidelines. This result was not surprising given that seven 
of the eight members of the review panel were members of 
IDSA, which selected the panel.8,9
Advances and contradictions
The unprecedented legal action against the IDSA Lyme 
guidelines reflected frustration over the widening gap 
between groundbreaking experimental evidence and 
entrenched clinical practices in Lyme disease.8,9 The past 
decade witnessed significant advances in understanding the 
pathogenesis of B. burgdorferi infection.10–16 The genome 
of B. burgdorferi was sequenced in its entirety, and the 
biologic and immunologic contribution of various genes 
was elucidated.10–12 In particular, the mechanisms of “stealth 
pathology” utilized by the Lyme spirochete in evading the 
host immune response and establishing infection in diverse 
tissues was illuminated.13–16 Animal models of Lyme dis-
ease in gerbils, hamsters, mice, dogs, monkeys, and horses 
provided evidence for persistent infection in various tissues 
following experimental transmission of B. burgdorferi.17–30 
In many of these models, infection persisted despite the 
equivalent of short-course antibiotic therapy.19–27
While progress was being made in research models of tick-
borne disease, controversy raged over the clinical features of 
Lyme disease.31–41 A growing number of studies highlighted 
persistent symptoms in patients following clinical infection 
with B. burgdorferi, but the pathologic mechanism of those 
symptoms remained murky.31–36 The concepts of ‘post-Lyme 
syndrome’, ‘post-treatment Lyme disease’, and ‘chronic 
Lyme disease’ were hotly debated, and the issues of postin-
fectious autoimmunity versus persistent spirochetal infection 
remained unsettled despite numerous studies from Europe 
and the United States that documented failure of short-course 
antibiotic therapy and persistent B. burgdorferi infection 
in various tissues (Appendix 1).33–36 The role of prolonged 
antibiotic therapy in patients with persistent Lyme symptoms 
was also debated based on conflicting study results involving 
a limited number of patients who had been symptomatic for 
long periods and had already failed similar treatment.42–47 The 
generalizability of these studies to the majority of patients with 
persistent Lyme symptoms was also questioned.47
Evidence for chronic infection
The comprehensive review of the IDSA Lyme guidelines 
provided strong evidence for chronic spirochetal infection in 
patients with persistent Lyme symptoms (Appendix 1).48–58 
This evidence was supported by ongoing studies showing 
failure of ‘standard’ antibiotic therapy in mice infected with 
the Lyme spirochete.20–24 Coupled with previous animal and 
human studies of persistent infection and antibiotic failure, 
this evidence underscores the importance of chronic infec-
tion in Lyme disease. It also raises many questions about the 
mechanism(s) and optimum therapy for persistent spirochetal 
illness.
Complementing the evidence in favor of chronic 
B. burgdorferi infection, clinical and experimental stud-
ies have shown that tick-borne coinfections may also have 
chronic phases.59–67 In the past, reports of pathology due to 
Babesia, Anaplasma, Ehrlichia, and Bartonella species have 
focused on the fulminant acute forms of infection that are 
relatively easy to diagnose and often fatal in immunocom-
promised patients.61,63,67 More recently, these organisms have 
been associated with chronic persistent infection in animal 
models and humans.59–67 The presence of coinfecting organ-
isms has been shown to enhance the symptoms and exacerbate 
the severity of Lyme disease.68–73 Thus recognition of chronic 
coinfections supports the concept of unresolved illness due 
to persistent infection with the Lyme spirochete.
Renewed interest in cell wall 
deficient bacterial forms
Cell wall-deficient (CWD) bacterial forms were first described 
in 1935 by Klieneberger, who named them L-forms after the 
Lister Institute where she worked.74 Subsequent research 
by Dienes showed that various bacteria could form CWD 
colonies and then revert back to bacillary morphology under 
appropriate conditions.75 An extensive review by Domingue Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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and Woody highlighted the extent of CWD morphology in 
many bacterial strains and the potential role of these mutant 
bacteria to produce persistent infection and chronic diseases.76 
The confusing terminology used to describe CWD bacteria 
has hindered work in this field. While the term ‘L-form’ or 
‘spheroplast’ describes CWD morphology in coccobacillary 
organisms, the term ‘cyst’ or ‘round body’ has been used to 
describe similar morphology in spirochetes.76
Margulis et al described CWD spirochetal forms in 1993.77 
Subsequently Preac-Mursic and colleagues demonstrated the 
formation and cultivation of B. burgdorferi ‘spheroplast-
L-form variants’,78 and Brorson et al showed that these 
forms, which he termed cysts or round bodies, could revert 
to viable spiral forms of the bacteria.79,80 This observation 
has been confirmed by other investigators.81–83 Although the 
pathogenicity of CWD borrelial forms has been questioned,3 
recent studies have suggested a link between CWD borrelia 
and neurodegenerative diseases,84–86 and resistance of cystic 
forms to antibiotic therapy has been documented.87–90 Recent 
advances in understanding molecular mechanisms of CWD 
bacterial formation has offered a glimpse at new treatment 
approaches to chronic Lyme disease.90 Currently the only 
antibiotic that reliably targets the cyst form of B. burgdorferi 
is metronidazole or its derivatives,87,88 while other agents 
have yielded negative or conflicting treatment results with 
cysts.23,89,90 Given the potential importance of CWD forms in 
persistent B. burgdorferi infection, newer antibiotics aimed 
at this evasive mutant are desperately needed to eradicate 
chronic infection in Lyme disease.85
Biofilms
Another mechanism of chronic infection involves the forma-
tion of biofilms.92–98 These adherent polysaccharide-based 
matrices protect bacteria from the hostile host environment 
and facilitate persistent infection. Biofilms are responsible 
for a number of chronic infections, including periodontitis, 
chronic otitis media, endocarditis, gastrointestinal infection, 
and chronic lung infection.92–98 Sapi and MacDonald raised 
the possibility of biofilm formation by B. burgdorferi, and 
subsequent work has demonstrated these spirochetal forma-
tions in culture and in the tick gut.99,100 Combinations of borre-
lial cysts and putative biofilms have also been noted in patient 
skin biopsies using focus floating microscopy.101 Biofilm 
formation is dependent on cyclic di-GMP expression,102,103 
and recent studies have shown that B. burgdorferi expresses 
this regulatory molecule.104,105 Coordinated steps in the elabo-
ration of biofilms have been demonstrated in other bacteria, 
and it remains to be seen whether similar molecular processes 
occur in borrelial strains and whether these processes play 
a role in persistent infection.106,107
To date no antibiotic treatment exists for biofilm for-
mation. However elucidation of the regulatory steps in the 
biofilm process should allow development of ‘designer’ 
  antibiotics that interfere with this process.106 It has recently 
been shown that mutations in genes that regulate biofilm 
development can interfere with the elaboration of new 
biofilms and also cause collapse of established biofilm 
colonies.107 These findings indicate the potential effective-
ness of newer antibiotics that target the biofilm regulatory 
process, suggesting a novel approach to treatment of Lyme 
disease and other chronic infections.108,109
Testing for Lyme disease
As we enter a new decade, clinical testing for Lyme disease 
remains abysmal.110–115 The two-tier algorithm recommended 
by the Centers for Disease Control and Prevention utilizes 
a screening enzyme-linked immunosorbent assay (ELISA) 
or immunofluorescence assay followed by a confirmatory 
Western blot. Although this approach has a high test specific-
ity, the sensitivity of the two-tier approach in Lyme disease 
patients tested at least 4 to 6 weeks after infection is only 
44% to 56%, which is inadequate for a clinical diagnostic 
test and, by comparison, far below the 99.5% sensitivity of 
diagnostic HIV testing.110,114,115 Furthermore, the misconcep-
tion that two-tier testing is highly sensitive for Lyme disease 
patients with persistent arthritic or neurologic symptoms 
derives from a study that selected patients based on positive 
Lyme testing and then showed high levels of two-tier test 
positivity.115 This circular reasoning is a systematic problem 
with the evaluation of Lyme testing.
There are a number of reasons for the inaccuracy of Lyme 
testing, including use of less antigenic laboratory spirochetal 
strains in the commercial test kits, elimination of important 
spirochetal target proteins from those kits, and lack of stan-
dardization of the commercial Lyme assays.111–113 Gender 
bias may also be a factor: while chronic Lyme disease is 
reportedly more common in women, the two-tier test sys-
tem yields positive results more often in men.116 Although a 
newer ELISA targeting the conserved VlsE or C6 peptide of 
B.   burgdorferi has been developed, this test system does not 
appear to be more sensitive than the two-tier approach.117,118 
While molecular testing has been useful for diagnostic confir-
mation and treatment monitoring in other illnesses, molecular 
testing for B. burgdorferi has been unreliable, and newer 
molecular techniques targeting tick-borne agents remain 
unproven and expensive.119,120 Assays for more accessible Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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surrogate markers of Lyme disease have yet to be accepted 
by the general medical community.121–125 Thus testing for 
Lyme disease remains problematic.
A newer approach to Lyme testing involves the use of 
proteomics.126,127 Based on the known genetic make-up of the 
spirochete, numerous proteins can be generated in vitro and 
tested for antigenicity using Lyme patient sera. In this man-
ner, novel target proteins can be identified, and conceivably 
new test systems based on these proteins can be developed 
without even knowing the function or location of the antigens 
within the spirochete.126 Work on these proteomic-based 
test systems is already in progress, but extensive clinical 
validation will be required to bring those tests to market. 
Nevertheless the proteomic approach to Lyme testing holds 
great promise for more accurate serological diagnosis, and 
development of proteomic testing for tick-borne diseases 
provides a useful diagnostic model for other chronic and 
elusive infections. Beyond proteomics, novel test systems that 
exploit electromagnetic signals generated by bacterial DNA 
sequences may also prove to be effective in the diagnosis of 
chronic Lyme disease.128,129
Big pharma is watching
Until now, the pharmaceutical industry has steered clear of 
Lyme disease. There are a number of reasons for this avoid-
ance, including the fear of entry into a controversial field 
and the perception that Lyme disease is easy to treat with 
short-course generic antibiotics. In simple terms, uncertainty 
about the disease and lack of profitable treatment options has 
limited pharmaceutical involvement in Lyme disease. This 
scenario is in stark contrast to the AIDS epidemic, where 
the prospect of billion-dollar antiviral sales propelled the 
pharmaceutical industry into a leading role in combating the 
pandemic.130,131 In a more recent example, the development 
of effective (and lucrative) drug therapy for fibromyalgia has 
boosted the status of that previously maligned diagnostic 
entity and fostered unprecedented awareness of the condi-
tion in the medical community and among the lay public.132 
The lack of a similar dynamic in Lyme disease has been a 
significant roadblock to progress in treating the tick-borne 
illness.
Progress in understanding the various aspects of Lyme 
disease outlined above should encourage the pharmaceutical 
industry to assume a more active role in the Lyme arena. The 
evidence for chronic infection with the Lyme spirochete and 
coinfecting organisms supports a greater need for antibiotic 
therapy in this disease beyond the 2 to 4 weeks specified in 
the discredited IDSA guidelines.133,134 The need for more 
effective treatment of this chronic infection in turn supports 
the use of more complex (and lucrative) antibiotic regimens 
in Lyme disease. In a similar vein, targeting CWD forms of 
B. burgdorferi and biofilm formation offers the prospect of 
new antibiotic approaches to the disease, with an exciting 
opportunity for innovative therapeutics and increased profits. 
Development of antibiotic agents that target spirochetal CWD 
forms and biofilms may also provide valuable insight into 
the treatment of other chronic infections. The development of 
more reliable testing for Lyme disease based on proteomics 
will help to define the population in need of these innova-
tive therapies. More reliable standardized testing will also 
assure reimbursement for newer Lyme therapies from third 
party payors.
Conclusions
In summary, extensive evidence now shows that persistent 
symptoms of Lyme disease are due to chronic infection with 
the Lyme spirochete in conjunction with other tick-borne 
coinfections. The mechanisms of chronic infection appear 
to involve CWD forms of the spirochete and biofilm forma-
tion, and these infectious processes are attractive targets for 
future drug development. Institution of more reliable Lyme 
testing based on proteomics should dispel uncertainty over 
the presence of the disease and facilitate targeting of patients 
who require treatment. The opportunity for the pharmaceuti-
cal industry to develop new drugs targeting novel infectious 
processes in a well-defined patient population will lead to 
broader recognition and more effective treatment of Lyme 
disease over the next decade.
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Appendix 1 Evidence for persistent infection following treatment of Lyme diseasea
Study/reference Study origin Persistence of B. burgdorferi 
shown by
Sample source
Weber et al1 Europe Histology Brain, liver (autopsy)b
Schmidli et al2 Europe Culture Synovial fluid
Cimmino et al3 Europe Histology Spleen
Preac-Mursic et al4 Europe Culture Skin Bx, CSF
Pfister et al5 Europe Culture CSF
Strle et al6 Europe Culture Skin Bx
Preac-Mursic et al7 Europe Culture Iris Bx
Haupl et al8 Europe Culture Ligament Bx
Strle et al9 Europe Culture Skin Bx
Preac-Mursic et al10 Europe Culture Skin Bx, CSF
Oksi et al11 Europe Culture CSF
PCR 
PCR
Brain Bx 
Brain (autopsy)
Priem et al12 Europe PCR Synovial Bx/fluid
Oksi et al13 Europe Culture, PCR Blood
Breier et al14 Europe Culture Skin Bx
Hunfeld et al15 Europe Culture Skin Bx
Hudson et al16 Australia Culture, PCR Skin Bx
Steere et al17 USA Histology Synovial Bx
Kirsch et al18 USA Histology LN (autopsy)
Liegner et al19 USA Histology Skin Bx
PCR Blood
Battafarano et al20 USA Histology, PCR Synovial Bx/fluid
Chancellor et al21 USA Histology Bladder Bx
Nocton et al22 USA PCR Synovial fluid
Shadick et al23 USA Histology Brain (autopsy)
Masters24 USA Culture Blood
Lawrence et al25 USA PCR CSF
Bayer et al26 USA PCR Urine
Nocton et al27 USA PCR CSF
Notes: aAll patients had received a minimum of 2 to 4 weeks of antibiotic therapy; bMother treated with antibiotics during pregnancy; newborn died.
Abbreviations: PCR, polymerase chain reaction; Bx, biopsy; CSF, cerebrospinal fluid; LN, lymph node.
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